When specific gut microbes reveal a possible link between hepatic steatosis and adipose tissue

Nonalcoholic Fatty Liver Disease in Children: Where Are We?

Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons

Common Genetic Variants and Nonalcoholic Fatty Liver Disease

The role of the gut microbiome in chronic liver disease: the clinical evidence revised.

Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins

Epidemiology of non-alcoholic fatty liver disease in China

Nonalcoholic fatty liver disease (NAFLD), the major reason for abnormal liver function in the Western world, is associated with obesity and diabetes and is characterized by insulin resistance (IR). IR is regulated by mediators released from cells of the immune system or adipocytes and proinflammatory cytokines such as tumor necrosis factor-α (TNFα). The importance of TNFα in human and animal fatty liver diseases, both caused by genetic manipulation and overnutrition, has been shown convincingly. Furthermore, neutralization of TNFα activity improves IR and fatty liver disease in animals. Adiponectin is a potent TNFα-neutralizing and anti-inflammatory adipokine and in vitro and experimental animal studies have proven the importance of this mediator in counteracting inflammation and IR. Anti-inflammatory effects of adiponectin are exerted both by suppressing TNFα synthesis and by induction of anti-inflammatory cytokines such as interleukin-10 or interleukin-1–receptor antagonist. Therefore, the balance between various mediators, either derived from the immune system or adipose tissue, appears to play an important role in hepatic and systemic insulin action and in the development of fatty liver disease.

Lean Fatty Liver Disease: Through Thick and Thin

Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology

Combined alcoholic and non-alcoholic steatohepatitis.

Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy

The Gut Microbiome in Health and Disease

Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

Yet more evidence that MAFLD is more than a name change